Steven Chmura MD, PhD

Steven J Chmura MD PhD. Professor and Chair of Breast Radiation ☢️ Oncology studying #oligometastases #EndCancer

[Sean Pitroda, M.D. @SeanPitroda]

Spatiotemporal control of CAR-T cell TNF release via tumor-targeted irradiation

https://t.co/vwF20a6Rj4

Congrats @rweichselbaum @KunleOdunsiMD @UCCancerCenter @UChicagoRadonc @Ludwig_Cancer

[NRG Oncology @NRGonc]

Whether you are new to NRG, transitioning into a new role, or taking on different clinical trials, the NRG Mentorship Program offers personalized support from experienced NRG members. Learn more ➡️https://t.co/NvxY7ax0fS

[Steven Chmura MD, PhD @Docace911]

@rweichselbaum @jryckman3 @CJTsaiMDPhD @NRGonc @SeanPitroda @JCO_ASCO @DavidKrugMD @CASRA_SABR @safaviaa @ChadTangMD @IBCradiation To clarify, the interaction was only in the ablation arm, not the systemic only arm.

[Prajnan Das @PrajnanDasMD]

Introducing our new Rad Onc faculty to pani puri and chaat @Enoch_Chang @StephDudzinski @RKouzyMD @adam_grippin @Docace911 Dr. Zhao, Dr. Cruttenden @UTMDAnderson

[Chad Tang, MD @ChadTangMD]

@rweichselbaum @TonyFelefly @pipcosper @CJTsaiMDPhD @subatomicdoc @Docace911 @NRGonc @SeanPitroda @JCO_ASCO @DavidKrugMD @CASRA_SABR @safaviaa @IBCradiation It’s worth noting there is actually another completed trial that is the largest of the bunch from Egypt. They were all newly diagnosed and the results were firmly negative.

https://t.co/5ZbmrV1Q2a

[Rita Nanda @RitaNandaMD]

Good to see this finally in print @Docace911!

[Steven Chmura MD, PhD @Docace911]

@MuzamilArshad18 @PrajnanDasMD @UTMDAnderson And hopefully dark matter is detected in our lifetime 🤔

[Steven Chmura MD, PhD @Docace911]

@rweichselbaum @TonyFelefly @pipcosper @CJTsaiMDPhD @subatomicdoc @NRGonc @SeanPitroda @JCO_ASCO @DavidKrugMD @CASRA_SABR @safaviaa @ChadTangMD @IBCradiation They are 2 different trials and different populations / lines of therapy / n.

[Steven Chmura MD, PhD @Docace911]

@ChadTangMD @rweichselbaum @TonyFelefly @pipcosper @CJTsaiMDPhD @subatomicdoc @NRGonc @SeanPitroda @JCO_ASCO @DavidKrugMD @CASRA_SABR @safaviaa @IBCradiation And the EXTEND trial from MD Anderson .

[Steven Chmura MD, PhD @Docace911]

@rweichselbaum @ilyassahinMD @JCO_ASCO The CTC data suggests just that . Please support the next generation of trials using response based (Swog s2511) or molecular selection (NRG Clarity) .

[Wendy Woodward MDPhD @IBCradiation]

@Icro_Meattini @JAMouabbi @DavidKrugMD @Docace911 CTCs interact with the arms - prompts the hypothesis that ablation is beneficial if micrometatstatic systemic disease is controlled. New concept being evaluated at NCI next month. 🤞🏻🤞🏻

[Steven Chmura MD, PhD @Docace911]

@TonyFelefly @5_utr The stratifications were done based on the assumption (which everyone assumed ) PFS would be better in ablation and the remaining 289 would accrue. Our prediction for PFS in the sbrt was spot on. Systemic only with oligo did very well. The forest plot was done as exploratory.

[lemmiwinks @lemmiwenks]

Such a Bright future. So many rockstars.

[Steven Chmura MD, PhD @Docace911]

@UCCancerCenter @JCO_ASCO @UChicagoMed @UChicagoBreast This statement is confusing. The trial as designed shows no benefit in PFS between treatment arms. The secondary endpoint shows selection with low or absent Ctc with ablation had a benefit . This is driving the next generation of trials . Thank you to all my UC collaborators!

[Steven Chmura MD, PhD @Docace911]

@SeanPitroda So what would be your endpoint if you allowed multiple rounds of sbrt on a stratified randomized trial?

[Steven Chmura MD, PhD @Docace911]

@ajuloorimd @jryckman3 @TonyFelefly @OncoAlert @safaviaa @CJTsaiMDPhD Oligoma inclusion allowed any line of therapy, although the slides appear to show only 1-2nd line. Br002 was 0-1st line only including de novo . The CTC plus imaging story lead by Dr Woodward @IBCradiation is the most interesting and will lead to the next trials @ChelainG

[Steven Chmura MD, PhD @Docace911]

@jryckman3 @safaviaa The inclusion states any line, however the presented data it appears all were 1-2nd.

[Steven Chmura MD, PhD @Docace911]

@TonyFelefly @DavidKrugMD Yes No and yes 🤣The primary also had to be controlled, 1/4 de novo. 60% single Met. The CTC plus imaging PFS finding in the SBRT lead be Dr Woodward @IBCradiation is really exciting and will lead to the next trial run by Dr Goodman @ChelainG

[Steven Chmura MD, PhD @Docace911]

@jryckman3 @ajuloorimd @TonyFelefly @OncoAlert @safaviaa @CJTsaiMDPhD Where are you seeing the “any number” in the inclusion criteria ?

[Steven Chmura MD, PhD @Docace911]

@5_utr @TonyFelefly @DavidKrugMD BR002 is a specific question in breast cancer. The CTC results suggest the next generation of trials must to incorporate molecular and imaging data or response adapted (Swog s2511). SABR-comet was a different trial with few breast cancers.